Ata Bethesda Cytology Management

ATA Bethesda Cytology Management Tool

Source: 2015 ATA Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Haugen et al. Thyroid 2016;26(1). DOI: 10.1089/thy.2015.0020

STEP 1 — Identify the Bethesda Category

*Malignancy risk based on surgical excision data from ATA Guidelines Table 6.

STEP 2 — Apply the Management Algorithm by Category

Bethesda I — Nondiagnostic / Unsatisfactory

• Action: Repeat FNA under ultrasound guidance
• Repeat after a minimum interval (allow any hematoma to resolve, typically 4–6 weeks)
• If repeat FNA is again nondiagnostic → consider surgical excision or close follow-up if the nodule is sonographically benign (very low suspicion)
• Cystic nodules with persistent nondiagnostic results + high-risk clinical features → consider surgery

Bethesda II — Benign

• Action: No immediate surgery
• Follow-up by sonographic pattern (see intervals below)
• Exceptions that warrant surgery/FNA despite benign cytology:
  • High-risk clinical features (radiation history, family history DTC, vocal cord palsy, progressive growth)
  • Symptomatic nodule (compression, dysphagia)
  • Focal 18FDG-PET avidity in the same nodule

Follow-up ultrasound intervals after benign FNA:

Two benign FNA results on the same nodule → US surveillance for malignancy no longer indicated (can discontinue FNA monitoring)

Bethesda III — AUS / FLUS

• Action: Clinical and sonographic risk stratification guides next step

Decision tree:

1. Repeat FNA (preferred initial approach)

   • Repeat after 3 months (allow inflammation to resolve)
   • Use US guidance; consider different sampling technique
   • ~50–75% of repeats yield a definitive category

2. Molecular testing (if repeat FNA not desired or if repeated AUS/FLUS)

   • Mutational panel (BRAF, RAS, RET/PTC, PAX8/PPARγ) or gene expression classifier
   • Positive/high-risk molecular profile → proceed as Bethesda V
   • Negative/low-risk → surveillance may be appropriate

3. Diagnostic surgery (lobectomy preferred)

   • Indicated if: high-risk sonographic features, high-risk clinical history, repeat FNA again AUS/FLUS, or patient preference

Bethesda IV — Follicular Neoplasm / Suspicious for FN

• Action: Diagnostic surgical excision (lobectomy)
• Rationale: Cannot distinguish follicular adenoma from follicular carcinoma on cytology alone (vascular/capsular invasion needed on histology)
• Molecular testing option:
  • If negative → observation may be considered (discuss with patient)
  • If positive → proceed to surgery as planned
• Hürthle cell variant: lobectomy is standard; Hürthle cell carcinoma has distinct biology

Bethesda V — Suspicious for Malignancy

• Action: Surgery — manage similarly to malignant cytology
• Near-total/total thyroidectomy if:
  • Nodule >4 cm
  • Bilateral nodular disease
  • High-risk clinical features
  • Patient preference
• Lobectomy may be sufficient if:
  • Nodule ≤4 cm
  • No clinical high-risk features
  • Absence of bilateral disease or lymphadenopathy

Bethesda VI — Malignant

• Action: Surgery generally recommended
• Approach depends on:
  • Tumor size and extent
  • Presence of lymphadenopathy
  • Comorbidities and patient preference

PTMC <1 cm without high-risk features: active surveillance without immediate surgery is an acceptable alternative in selected patients

STEP 3 — Preoperative Assessment Before Surgery (Bethesda IV–VI)

• Neck ultrasound: Evaluate cervical lymph nodes (central and lateral compartments) preoperatively
  • FNA any suspicious node (with Tg washout if needed)
• Vocal cord assessment: If hoarseness, voice change, or prior neck surgery → laryngoscopy
• Do NOT routinely perform: CT neck, PET scan, or bone scan — not indicated for standard low-risk workup

CLINICAL GUARDRAILS

• Bethesda II ≠ dismiss — still requires US follow-up; two benign results on the same nodule over time can justify discontinuing surveillance
• AUS/FLUS is not a diagnosis — it is a category mandating further characterisation, not a final answer
• Molecular testing augments but does not replace surgical judgment for Bethesda III/IV — a negative panel lowers but does not eliminate risk
• Lobectomy is not inferior to total thyroidectomy for well-selected low-risk DTC — do not reflexively escalate to total thyroidectomy
• Active surveillance for PTMC is evidence-based; counsel patient on the option before recommending immediate surgery
• High-risk clinical context overrides cytology — a "benign" FNA in a patient with rapid growth, fixation, or lymphadenopathy should trigger surgical referral regardless of Bethesda category